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BEAM AUTOGRAFT IN A DIALYSIS PATIENT: A CASE REPORT
Booth, D.1 1Royal Melbourne Hospital, Melbourne, Victoria, Australia.
In September 2004 YC was diagnosed with relapsed Hodgkin
Disease as an incidental ﬁnding during work up for a renal trans-
plant for reﬂux nephropathy. Despite her dependence on haemo-
dialysis three times a week, she was only 24 years old and otherwise
well so she was planned for salvage chemotherapy. Treatment
consisted of stemcell mobilisation with dose modiﬁed cyclophos-
phamide and G-CSF followed by two cycles of modiﬁed ADEC
(cytarabine, dexamethasone, etoposide and cyclophosphamide) fol-
lowed by BEAM autograft. Very little information was available to
guide dosing for conditioning in this patient. A 50% dose reduc-
tion was selected for melphalan and serum melphalan levels were
collected 5minutes and 12hours post dose. Both levels were lower
than the range observed in patients with normal renal function.
Dose reduction of melphalan for renal dysfunction may not be
appropriate even in patients on dialysis. YC is alive and in remis-
sion 2 years after her transplant.
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A DOUBLE BLINDED PILOT STUDY OF APREPITANT VS PLACEBO COM-
BINED WITH STANDARD ANTIEMETICS FOR THE CONTROL OF NAUSEA
AND VOMITING DURING HEMATOPOIETIC CELL TRANSPLANTATION
Bubalo, J.S.1, Leis, J.F.1, Curtin, P.T.1, Kovascovics, T.J.1,
Meyers, G.1, Hayes-Lattin, B.1, Jones, N.1, McCune, J.S.2,
Munar, M.Y.3 1Oregon Health & Science University Hospital and
Clinics, Portland, OR; 2Fred Hutchinson Cancer Research Center, Se-
attle, WA; 3Oregon State Univerisity College of Pharmacy, Portland,
OR.
Despite advances in antiemetic therapy, HSCT conditioning
regimens of high dose chemotherapy /- TBI, continue to cause
signiﬁcant rates of nausea and vomiting (N/V). The role of the
neurokinin antagonist, aprepitant (A), when added to standard
antiemetic therapy was investigated to determine if it improved
control of N/V. During cyclophosphamide-based conditioning
therapy patients were randomized to receive ondansetron (O) /-
dexamethasone plus A or a placebo (P) on days of chemo/radio-
therapy. The primary aim of this study was to reduce N/V both
during and after HSCT conditioning. Nausea, emesis, and nutri-
tional intake, were evaluated from the start of conditioning
through day 7. Since A is a substrate & moderate inhibitor of
CYP4503A4, busulfan dosing was targeted to disease appropriate
AUCs & pharmacokinetic (PK) analysis was performed on cyclo-
phosphamide (Cy), metabolites (HCY & CEPM), and A. Patients
were similar demographically for age & gender with 10 patients
randomized per arm. Nine patients received TBI (1200 cGy) CY
(120 mg/kg) and 11 received Bu (16 mg/kg) CY (120 mg/kg). A/P
was begun on Day –7 (125 mg) with the ﬁrst O dose and continued
daily (80 mg) through day 4 (alone on days –1 through 4).
Responses were deﬁned as complete (CR), no emesis, mild-mod-
erate nausea, and major (MR), 1-2 emesis on only 1 day with any
level nausea or no emesis with severe nausea. Overall responses
(CR  MR) were seen in 9/10 A patients and 4/10 P patients.
(p0.03) Reviewing emesis solely, no emesis was seen in 7/10 A
patients and 4/10 P patients (p0.18). Preliminary PK show the
observed AUCs of CY, HCY and CEPM for both preparative
regimens were within the lower range of previously reported data
and the PK differences between regimens were also consistent with
previous data. All patients in both arms required busulfan dose
adjustments (primarily reductions) to stay within target AUCs.
Anti-seizure prophylaxis with phenytoin may signiﬁcantly decrease
A levels, but this didn’t appear to be clinically relevant in this study
and further PK evaluation is needed. Adverse effects were similar
between arms with one case of sinusoidal obstruction syndrome in
the P arm.
In this interim analysis, aprepitant added to standard antiemetics
provides improvement in emesis prevention over standard anti-
emetics alone during cyclophosphamide-containing conditioning
therapy prior to HSCT, without signiﬁcant changes in cyclophos-
phamide pharmacokinetics or increased toxicity.
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USE OF LOW DOSE RASBURICASE IN THE MANAGEMENT OF HYPER-
URICEMIA IN TUMOR LYSIS SYNDROME
Jin, R.1, Shayani, S.1, Htoy, S.1, Fujinami, W.1 1City of Hope National
Medical Center, Duarte, CA.
Background: Hyperuricemia is a complication of tumor lysis
syndrome (TLS) in patients with high grade lymphomas, leuke-
mias, and bulky tumors. Rasburicase is a recombinant form of urate
oxidase which converts uric acid to a more soluble form, allantoin.
It is indicated for the management of hyperuricemia in tumor lysis
syndrome. City of Hope is a National Cancer Institute (NCI)
designated comprehensive cancer center specializing in oncology,
hematology, and hematopoietic stem cell transplantation (HSCT).
The primary goal of this study is to determine the efﬁcacy of
low-dose rasburicase in treatment of hyperuricemia secondary to
TLS. Based on the previous experience with low-dose rasburicase
at City of Hope and small studies supporting the use of low-dose
rasburicase, a TLS management guideline was developed in No-
vember 2005, using low-dose rasburicase. The guidelines also
address the proper handling of the blood samples, since laboratory
techniques in collecting and processing blood specimen are critical
in obtaining accurate uric acid levels.
Methods: This study compared the efﬁcacy of low-dose ras-
buricase versus the manufacturer recommended dose of 0.15-
0.2mg/kg for ﬁve days both pre-guideline and post-guideline from
January 2002 to April 2006. For the purpose of this study, doses
less than 0.13 mg/kg would be considered low-dose and doses
greater than or equal to 0.13mg/kg would be considered standard
dose.
Results: Data was collected from the pharmacy information
system, hospital record system, patient charts, and the laboratory
information system. Uric acid levels collected at baseline and post-
treatment, and serum creatinine levels were reviewed. The percent
successful treatment in both low-dose and standard-dose ras-
buricase was 100%. The percent serum uric acid level decline
within 24 hours of rasburicase administration was 73% pre-guide-
line and 79% post-guideline for a low-dose treatment group and
92% pre-guideline and 97% post guideline for a standard-dose
treatment group.
Conclusion: This retrospective study shows that although the
magnitude of serum uric acid level decline differs between the pre-
and post-treatment groups, low-dose rasburicase is as effective as
the standard-dose rasburicase in normalizing serum uric acid lev-
els.
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TRIAZOLE-RESISTANT CANDIDA GLABRATA ORAL CANDIDIASIS AND
ASSOCIATED GASTROINTESTINAL SYNDROME IN ALLOGENEIC HEMA-
TOPOIETIC CELL TRANSPLANT: SUCCESSFUL TREATMENT WITH ORAL
AMPHOTERICIN B
Oholendt, M.S.1, Darcourt, J.1, Kamble, R.1, Carrum, G.1 1Center for
Cell and Gene Therapy, Baylor College of Medicine and The Methodist
Hospital, Houston, TX.
Oral candidiasis (OC) is common in patients undergoing he-
matopoietic cell transplant (HCT). Candida glabrata, the second
most frequently isolated species in OC, has proven more difﬁ-
cult to treat and usually presents asymptomatically. The clinical
signiﬁcance of symptoms is contentious and the literature lacks
effective therapeutic guidelines for treatment. We herein de-
scribe a series of 6 HCT patients with OC due to triazole-
resistant C. glabrata. The data were prospectively collected.
Mouth swabs for fungal stain, culture and sensitivity were sent
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from oral lesions and clinical symptoms recorded. The median
age of the 4 females and 2 males was 50.5 years. All patients had
signs of OC with tongue plaques manifesting at a median of 86
days post-HCT (range 30-1045) and symptoms of dry mouth,
anorexia, nausea and/or vomiting. Dysguesia was noted in three
patients and weight loss in ﬁve (median 18 kg). None had
odynophagia and EGD performed in 3 patients was negative for
esophageal candidiasis. A total of 24 isolates were evaluated,
with those tested being resistant to ﬂuconazole, itraconazole,
and voriconazole with respective MIC’s of 256 /ml, 44 /ml
and 14.7 /ml. All isolates were sensitive to amphotericin B
(MIC 0.38 /ml). Concurrent systemic antifungal therapy at the
time of diagnosis of OC comprised: ﬂuconazole, voriconazole,
caspofungin or micafungin, or combination regimens of caspo-
fungin, micafungin, or amphotericin B lipid complex with vori-
conazole. The signs and symptoms persisted despite continua-
tion or alterations in the systemic antifungal regimen. Topical
application to the oral mucosa (5 ml 2-4 times/day) of ampho-
tericin B oral suspension (ABOS), prepared by the pharmacy at
a concentration of 100 mg/ml, resulted in dramatic clinical
response with rapid resolution of symptoms in all 6 patients. OC
relapsed at a median of 65.3 days in all the patients necessitating
re-treatment with ABOS. All patients rapidly responded. We
conclude that ABOS provides a simple, highly effective and
low-cost option for treatment of C. glabrata OC. The use of
newer antifungal agents combined with the incidence and mor-
bidity of other non-albicans OC infections may provide future
directions of study.
HCT Patient Characteristics
Age Sex Diagnosis
Transplant
Characteristics
GI
GvHD
Concurrent
Antifungal
Therapy
39 F CML-BC MRD, Cy/TBI (12
Gy)
Acute FLUC, VORI
51 M MM/PCL MRD, Flu/Mel/Cam Chronic FLUC, VORI
47 F T-ALL/AML MMUD, Cy/TBI/
Cam (12 Gy)
N/A FLUC
60 F DLBCL/NHL MUD, Flu/Mel/Cam Acute VORI, CASP,
MICA
50 F CML-BC MMUD, Flu/TBI/
Cam/CD45 (4.5
Gy)
N/A VORI, CASP,
ABLC, MICA
58 M MDS MRD, Flu/TBI/Cam
(4.5 Gy)
Chronic FLUC, VORI,
CASP, MICA
Abbreviations: CML-BC: Chronic Myelogenous Leukemia in
Blast Crisis; MM/PCL: Multiple Myeloma/ Plasma Cell Leu-
kemia; T-ALL/AML: T-cell Acute Lymphoblastic Leukemia/
Acute Myeloblastic Leukemia; DLBCL/NHL: Diffuse Large
B-cell Lymphoma/Non Hodgkin’s Lymphoma; MDS: Myelo-
dysplastic Syndrome; MRD: Matched Related Donor;
MMUD: Mis-matched Unrelated Donor; MUD: Matched Un-
related Donor; Cy: Cyclophosphamide; TBI: Total Body Irra-
diation; Flu: Fludarabine; Mel: Melphalan; Cam: Alemtu-
zumab; CD45: Investigational Anti-CD45 Monoclonal
Antibody; FLUC: Fluconazole; VORI: Voriconazole; CASP:
Caspofungin; MICA: Micafungin; ABLC: Amphotericin B
Lipid Complex
428
PALONOSETRON FOR THE PREVENTION OF ACUTE AND DELAYED
NAUSEA AND VOMITING FOLLOWING HIGH DOSE MELPHALAN AND
AUTOLOGOUS STEM CELL TRANSPLANTATION
Triﬁlio, S.1, Pi, J.1, Fishman, M.1, Masino, K.1, Kaniecki, K.1,
Mehta, J.1 1Northwestern Memorial Hospital, Chicago, IL.
Recipients of autologous stem cell transplanatation(HSCT) with
high dose melphalan universally experience signiﬁcant acute and
delayed nausea and vomiting(N/V)(60-100%), with the number of
emetic episodes typically increasing over advancing days. Currently
no drugs with FDA approval for delayed N/V have been studied in
recipients of HSCT. Palonosetron, a serotonin antagonist(5HT3)
with a prolonged duration of action, is approved for acute and
delayed onset N/V following moderate to highly emetogenic che-
motherapy. A retrospecive study was undertaken to determine if
the type of 5HT3 used, affected the amount of N/V experienced
and the number of antiemetics used to treat breakthrough N/V.
The treatment group included 25 myeloma patients who received
0.25mg palonsetron prior to HDM followed by HSCT. Melphalan
dose(m2) 200mg(n22),140mg(n2) 100mg(n1). The control
group was comprised of 49 patients who received 24mg IV ondan-
setron prior to HDM. The groups were otherwise compara-
ble.There were no scheduled anti-emetic from day0 onwards, and
anti-emetics were administered “as needed” based on patient needs
as asssessed by nurse clinician or clinical rounds team. As needed
meds includeed lorazepam , prochlorperazine, metoclopramide,
promethazine, ondansetron alone or in combination. Evaluation of
nausea and vomiting was assessed via interview with patient and
review of input/output in medical chart.
Table 1 shows results of palonosetron versus ondansetron and
the use of breakthrough medications. There was a statistically
signiﬁcant reduction in the number of breakthrough medications
needed for both acute and delayed N/V with respect to any break-
though medications(days 1-4) or versus additional ondansetron
only((all 7days). In addition , cost analysis revealed the following-
(all quoted from Redbook 2006): Average daily cost of break-
through medications for palonosetron and ondansetron group 
$14.00 and $56.20 respectively. Average overall cost/patient(in-
cluding prevention) for palonosetron  $477 versus ondanse-
tron.$511. There were no differences in time to engraftment or
signiﬁcnat side effects between groups.
We conclude that the use of palonosetron before HDM prior to
autologous transplantation was more effective that ondansetron in
controlling acute and delayed nausea and vomiting and improving
quality of life. In addition, because of its long duration of action,
palonosetron decreased the need for additional 5HT3 antagonists
leading to overall cost savings.
Breakthrough nausea and vomiting
Day
0-HSCT
Nausea/
Vomiting
(%)
any drug used for breakthrough ondansetron used for breakthrough
Palonosetron
(n25)
Ondansetron
(n49) P-value
Palonosetron
(n25)
Ondansetron
(n49) P-value
0 7/3 30 84 <.001 0 41 <.001
1 48/26 48 78 <.024 4 51 <.001
2 60/7 66 86 <.05 11 59 <.05
3 48/10 48 92 <.001 15 59 <.05
4 55/18 66 90 <.04 11 47 <.01
5 37/7 70 84 ns 15 53 <.006
6 40/25 60 86 <.05 19 47 <.05
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VORICONAZOLE PROPHYLAXIS IN PATIENTS AT HIGH RISK FOR INVA-
SIVE FUNGAL INFECTIONS FOLLOWING ALLOGENEIC HEMATAPOETIC
STEM CELL TRANSPLANTION
Triﬁlio, S.1, Singhal, S.1, Williams, S.1, Winter, J.1, Tallman, M.1,
Gordon, L.1, Evens, A.1, Frankfurt, O.1, Pi, J.1, Mehta, J.1 1North-
western Memorial Hospital, Chicago, IL.
Voriconazole is a triazole antifungal agent with good activity
against Aspergillus spp. Standard antifungal prophylaxis at NMH
for recipients of allogeniec HSCT is itraconazole 200mg po bid.
Voriconazole 200mg po bid is substituted on day0 of transplant if
they have prior history of Aspergillus infection(secondary prophy-
laxis) or switched from itraconazole to voriconazole with receipt of
high dose steroids(methylprednisolone 2mg/kg) for GVHD. Vori-
conazole is discontinued 30 days after immunosuppression is
stopped. 80 allograft recipients who received voriconazole and in
whom complete microbiologic and pharmacokinetic data were
available were studied to determine the efﬁcacy of voriconazole in
preventing invasive fungal infections (IFI). 24 patients had no
itraconazole prophylaxis. The remainder (n56) received itracon-
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